SpringerLink
Log in

CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status

  • Article
  • Published:
Cancer Gene Therapy Submit manuscript

Abstract

Chaperonin-containing TCP1 (CCT) is a multi-subunit complex, known to participate the correct folding of many proteins. Currently, the mechanism underlying CCT subunits in cancer progression is incompletely understood. Based on data analysis, the expression of CCT subunit 6 A (CCT6A) is found higher than the other subunits of CCT and correlated with an unfavorable prognosis in colon cancer. Here, we find CCT6A silencing suppresses colon cancer proliferation and survival phenotype in vitro and in vivo. CCT6A plays a role in cellular process, including the cell cycle, p53, and apoptosis signaling pathways. Further investigations have shown direct binding between CCT6A and both Wtp53 and Mutp53, and BIRC5 is found to act downstream of CCT6A. The highlight is that CCT6A inhibition significantly reduces BIRC5 expression independent of Wtp53 levels in Wtp53 cells. Conversely, in Mutp53 cells, downregulation of BIRC5 by CCT6A inhibition mainly depends on Mutp53 levels. Additionally, combined CCT6A inhibition and Wtp53 overexpression in Mutp53 cell lines effectively suppresses cell proliferation. It is concluded CCT6A is a potential oncogene that influences BIRC5 through distinct pathways in Wtp53 and Mutp53 cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Chaperonin-containing TCP-1 ζ subunit (CCT6A) was upregulated in colon cancer tissues and found to be a risk factor for the survival of patients with colon cancer.
Fig. 2: Low expression of CCT6A inhibits colon cancer development in vivo and in vitro.
Fig. 3: The cellular processes and features of genes influenced by CCT6A knockdown.
Fig. 4: Downregulation of CCT6A results in Mutp53 degradation but not Wtp53.
Fig. 5: Downregulation of CCT6A inhibits BIRC5 directly in Wtp53 cells but is mediated by Mutp53 in Mutp53 cells.
Fig. 6: Downregulation of CCT6A contributes to the antitumor activity of Wtp53.
Fig. 7: BIRC5 is required for CCT6A to facilitate colon cancer cell survival.

Data availability

The data supporting the RNA-Seq findings of this study are openly available at TCGA (https://portal.gdc.cancer.gov/). Data supporting the gene expression profile matrix files (GSE10950, GSE8671, and GSE41258) of this study are available in the GEO database (https://www.ncbi.nlm.nih.gov/geo/).

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70:7–30.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA A Cancer J Clin. 2017;67:7–30.

    Article  Google Scholar 

  3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA A Cancer J Clin. 2017;67:177–93.

    Article  Google Scholar 

  4. Leitner A, Joachimiak LA, Bracher A, Monkemeyer L, Walzthoeni T, Chen B, et al. The molecular architecture of the eukaryotic chaperonin TRiC/CCT. Structure. 2012;20:814–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Meyer AS, Gillespie JR, Walther D, Millet IS, Doniach S, Frydman J. Closing the folding chamber of the eukaryotic chaperonin requires the transition state of ATP hydrolysis. Cell. 2003;113:369–81.

    Article  CAS  PubMed  Google Scholar 

  6. Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and quality control. Science. 2016;353:aac4354.

    Article  PubMed  Google Scholar 

  7. Balchin D, Milicic G, Strauss M, Hayer-Hartl M, Hartl FU. Pathway of actin folding directed by the eukaryotic chaperonin TRiC. Cell. 2018;174:1507–21.e1516.

    Article  CAS  PubMed  Google Scholar 

  8. Gestaut D, Roh SH, Ma B, Pintilie G, Joachimiak LA, Leitner A, et al. The chaperonin TRiC/CCT associates with prefoldin through a conserved electrostatic interface essential for cellular proteostasis. Cell. 2019;117:751–65.e15.

  9. Yao L, Zou X, Liu L. The TCP1 ring complex is associated with malignancy and poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2019;12:3329–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Li W, Liu J, Zhao H. Prognostic power of a chaperonin containing TCP-1 subunit genes panel for hepatocellular carcinoma. Front Genetics. 2021;12:668871.

    Article  CAS  Google Scholar 

  11. Guest ST, Kratche ZR, Bollig-Fischer A, Haddad R, Ethier SP. Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes. Exp cell Res. 2015;332:223–35.

    Article  CAS  PubMed  Google Scholar 

  12. Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, Murray GI. Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol. 2006;210:351–7.

    Article  CAS  PubMed  Google Scholar 

  13. Yin H, Miao X, Wu Y, Wei Y, Zong G, Yang S, et al. The role of the Chaperonin containing t-complex polypeptide 1, subunit 8 (CCT8) in B-cell non-Hodgkin’s lymphoma. Leukemia Res. 2016;45:59–67.

    Article  CAS  Google Scholar 

  14. **ang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, et al. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci USA. 2008;105:12463–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66:105–43.

    Article  CAS  PubMed  Google Scholar 

  16. Ying Z, Tian H, Li Y, Lian R, Li W, Wu S, et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF-beta signaling. J Clin Invest. 2017;127:1725–40.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tanic N, Brkic G, Dimitrijevic B, Dedovic-Tanic N, Gefen N, Benharroch D, et al. Identification of differentially expressed mRNA transcripts in drug-resistant versus parental human melanoma cell lines. Anticancer Res. 2006;26:2137–42.

    CAS  PubMed  Google Scholar 

  18. Myung JK, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci. 2004;2:8.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hassin O, Nataraj NB, Shreberk-Shaked M, Aylon Y, Yaeger R, Fontemaggi G, et al. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat Commun. 2022;13:2800.

  20. Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2019;11:267–76.

    Article  CAS  PubMed  Google Scholar 

  21. Huang Y, Liu N, Liu J, Liu Y, Zhang C, Long S, et al. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle. 2019;18:3442–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhao Y, Li Y, Sheng J, Wu F, Song W. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs. J Exp Clin Cancer Res. 2019;38:379.

  25. Garg A, Hazra JP, Sannigrahi M, Rakshit S, Sinha S. Variable mutations at the P53-R273 oncogenic hotspot position leads to altered roperties. Biophys J. 2019;118:720–8.

  26. Lei, J. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations. Phys Chem Chem Phys. 2020;22:23032.

  27. Tan BS, Tiong KH, Choo HL, Fei-Lei Chung F, Hii LW, Tan SH, et al. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015;6:e1826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rochette PJ, Bastien N, Lavoie J, Guérin SL, Drouin R. SW480, a p53 double-mutant cell line retains proficiency for some p53 functions. J Mol Biol. 2005;352:44–57.

    Article  CAS  PubMed  Google Scholar 

  29. Ambrosini G, Adida C, Altieri DC, Ambrosini G, Adida C, Altieri DCA. novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.

    Article  CAS  PubMed  Google Scholar 

  30. Yoshida A, Zokumasu K, Wano Y, Yamauchi T, Imamura S, Takagi K, et al. Marked upregulation of survivin and aurora-B kinase is associated with disease progression in the myelodysplastic syndromes. Haematologica. 2012;97:1372–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sah NK, Seniya C. Survivin splice variants and their diagnostic significance. Tumor Biol. 2015;36:6623–31.

    Article  CAS  Google Scholar 

  32. Mirza A, Mcguirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–22.

    Article  CAS  PubMed  Google Scholar 

  33. Tang Q, Efe G, Chiarella AM, Leung J, Chen M, Yamazoe T, et al. Mutant p53 regulates survivin to foster lung metastasis. Genes Dev. 2021;35:528–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene. 2004;23:8146–53.

    Article  CAS  PubMed  Google Scholar 

  35. Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev. 2013;33:765–89.

    Article  CAS  PubMed  Google Scholar 

  36. Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: A promising tumor biomarker. Cancer Lett. 2007;249:49–60.

    Article  CAS  PubMed  Google Scholar 

  37. Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. Diagn Pathol. 2014;9:221.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Roh SH, Kasembeli M, Bakthavatsalam D, Chiu W, Tweardy DJ. Contribution of the type II chaperonin, TRiC/CCT, to oncogenesis. Int J Mol Sci. 2015;16:26706–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Boudiaf-Benmammar C, Cresteil T, Melki R. The cytosolic chaperonin CCT/TRiC and cancer cell proliferation. PLoS One. 2013;8:e60895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604.

    Article  CAS  PubMed  Google Scholar 

  41. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.

    Article  CAS  PubMed  Google Scholar 

  42. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–4.

    Article  CAS  PubMed  Google Scholar 

  43. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–95.

    Article  CAS  PubMed  Google Scholar 

  44. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–23.

    Article  CAS  PubMed  Google Scholar 

  45. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–4.

    CAS  PubMed  Google Scholar 

  46. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100–4.

    Article  PubMed  Google Scholar 

  47. Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene. 2007;26:290–7.

    Article  PubMed  Google Scholar 

  48. Yang X, **ong G, Chen X, Xu X, Wang K, Fu Y, et al. Survivin expression in esophageal cancer: correlation with p53 mutations and promoter polymorphism. Dis Esophagus. 2009;22:223–30.

    Article  PubMed  Google Scholar 

  49. Pizem J, Cör A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology. 2004;45:180–6.

    Article  CAS  PubMed  Google Scholar 

  50. Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol. 2005;27:1215–21.

    CAS  PubMed  Google Scholar 

  51. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999–6002.

    Article  CAS  PubMed  Google Scholar 

  52. Faivre J, Ponnelle T, Plenchette S, Chapusot C, Martin L, Piard F, et al. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. 2005;131:504–10.

  53. Liu J, Huang L, Zhu Y, He Y, Zhang W, Lei T, et al. Exploring the expression and prognostic value of the TCP1 ring complex in hepatocellular carcinoma and overexpressing Its s5 promotes HCC tumorigenesis. Front Oncol. 2021;11:739660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2022;22:127–44.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Zache N, Lambert JMR, Rökaeus N, Shen J, Bykov VJN. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol. 2017;11:595–5.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Bou-Hanna C, Jarry A, Lode L, Schmitz I, Schulze-Osthoff K, Kury S, et al. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett. 2015;359:211–7.

    Article  CAS  PubMed  Google Scholar 

  57. Sicari D, Fantuz M, Bellazzo A, Valentino E, Apollonio M, Pontisso I. et al. Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene. 2019;38:6184–95.

  58. Capaci V, Bascetta L, Fantuz M, Beznoussenko GV, Sommaggio R, Cancila V, et al. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nat Commun. 2020;11:3945.

  59. Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897–909.

  60. Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 2004;23:7545–51.

    Article  CAS  PubMed  Google Scholar 

  61. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004;314:902–7.

    Article  CAS  PubMed  Google Scholar 

  62. Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SBSM, et al. Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with aurora-B. Oral Oncol. 2010;46:263–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to all the study participants for tissue and data donations. This work was financially supported by Chongqing Key Clinical Specialty Construction Project for Department of Oncology (No. ZDZK-202105) and a Hospital-Level Project Grant from Chongqing University Three Gorges Hospital (No. 2022YJKYXM-042).

Author information

Author notes

  1. These authors contributed equally: Han Zhang, Taotao Zheng.

Authors and Affiliations

  1. Department of Oncology, Chongqing University Three Gorges Hospital, Chongqing, China

    Han Zhang, ** Huang, Qiang Liu, Shichuan Chang, Li Zhang, **g Guo, Yao Zhang & Huawen Liu

  2. School of Medicine, Chongqing University, Chongqing, China

    Taotao Zheng & Huawen Liu

  3. Department of Gastrointestinal Surgery, Chongqing University Three Gorges Hospital, Chongqing, China

    Chuan Qin

  4. School of Life Science and Technology, Mianyang Teacher’s College, Mianyang, Sichuan, China

    Chunxiang Bian

Authors
  1. Han Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taotao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chuan Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. **nyue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Han Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. ** Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shichuan Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. **g Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chunxiang Bian
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Huawen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HZ, CB and HL designed the experiments and drafted the manuscript; CB constructed the plasmids; TZ and HZ performed western blot and qPCR experiments; CQ and XZ analyzed the data; HL, XH and QL performed animal experiments; SC and LZ performed cell culture; JG and YZ gave suggestions to the revision of the manuscript; All authors approved the final manuscript and agreed to be accountable for all aspects of the work.

Corresponding authors

Correspondence to Chunxiang Bian or Huawen Liu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics

Mouse experiments were approved by the Institutional Animal Care and Use Committee of the Chongqing University Three Gorges Hospital (Chongqing, China) and were performed according to the institutional guidelines and protocols (No.SXYYDW2022-008).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, H., Zheng, T., Qin, C. et al. CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status. Cancer Gene Ther (2024). https://doi.org/10.1038/s41417-024-00806-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41417-024-00806-3

  • Springer Nature America, Inc.

Search

Navigation